Pharmacological basis of different targets for the treatment of atherosclerosis.
about
Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO miceTargeting platelets for prevention and treatment of cardiovascular disease.Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway.Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins.Antiinflammatory activity of Phyllanthus emblica, Plumbago zeylanica and Cyperus rotundus in acute models of inflammation.Molecular Mechanisms of Cardioprotective Actions of Tanshinones
P2860
Pharmacological basis of different targets for the treatment of atherosclerosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pharmacological basis of different targets for the treatment of atherosclerosis.
@ast
Pharmacological basis of different targets for the treatment of atherosclerosis.
@en
type
label
Pharmacological basis of different targets for the treatment of atherosclerosis.
@ast
Pharmacological basis of different targets for the treatment of atherosclerosis.
@en
prefLabel
Pharmacological basis of different targets for the treatment of atherosclerosis.
@ast
Pharmacological basis of different targets for the treatment of atherosclerosis.
@en
P2093
P2860
P1476
Pharmacological basis of different targets for the treatment of atherosclerosis
@en
P2093
Amarjit S Arneja
Harjot K Saini
Naranjan S Dhalla
Paramjit S Tappia
Yan-Jun Xu
P2860
P304
P356
10.1111/J.1582-4934.2005.TB00382.X
P577
2005-10-01T00:00:00Z